Anne Dorrance, Ph.D.

  • Cardiovascular Staff, Drug Discovery and Receptor Faculty, Online Faculty

Pharmacology & Toxicology
Associate Professor
Associate Chair
B340 Life Sciences
1355 Bogue Street
East Lansing, MI 48824
Email: dorranc3@msu.edu
Phone: 517-432-7403
Fax: 517-353-8915

Fields of Interest: The Dorrance Lab is dedicated to identifying novel mechanisms to improve the outcome of acute ischemic stroke.

Anne Dorrance on MSU Scholars

Educational Background

  • 1993 - B.Sc., Biological Sciences, University of Edinburgh/Scotland
  • 1997 - Ph.D., Medicine and Therapeutics, University of Glasgow/Scotland
  • 1997-1999 - Postdoctoral Fellow, Internal Medicine, The University of Michigan
  • July-Dec 1999 - Postdoctoral Fellow, Physiology, The University of Michigan
  • 2000 - Postdoctoral Fellow, Physiology, The Medical College of Georgia
  • 2001 - Research Scientist, Physiology, The Medical College of Georgia
  • 2001-2007 - Assistant Professor, Physiology, The Medical College of Georgia
  • 2007-present - Associate Professor, Pharmacology & Toxicology, Michigan State Univ
  • 2007-present - Adjunct Associate Prof, Neurology & Ophthalmology, Michigan State Univ

Biography & Current Research

Research Synopsis

Stroke is the third leading cause of death in the U.S., and the leading cause of long-term disability yet the treatment options available for stroke are extremely limited. The Dorrance Lab is dedicated to identifying novel mechanisms to improve the outcome of acute ischemic stroke. We are interested in understanding how disease like hypertension and obesity increase an individual’s risk of having a stroke. Our studies focus on the cerebral vasculature and on the blood brain barrier (BBB). Many of our studies utilize methods to visualize the cerebral blood vessels (Fig 1), but we also use basic biochemistry and molecular biology techniques.

Current Projects in the Lab

  • To evaluate the effects of mineralocorticoid receptor activation on cerebral vessel structure and function. We have been testing the usefulness of spironolactone, a mineralocorticoid receptor (MR) antagonist, to prevent and reverse cerebral vessel remodeling and reduce the damage caused by a stroke. Our current studies suggest that increased inflammatory cell infiltration is a key mediator of the damage caused by MR activation.
  • To study the affects of aldosterone and MR activation on BBB function. We know that breakdown of the BBB increases the damage caused by acute ischemic stroke; we are investigating if MR activation is involved in this process.
  • To study the effects of obesity on the cerebral vasculature. This project uses a model of obesity that was developed in our lab to study the effect of life long obesity on the vasculature. This model reflects the current trend in our population where obesity begins at a young age and continues into adulthood.

Awards & Achievements

Awards

  • 2008, Established Investigator Award, American Heart Association
  • 2004, Fellow of the American Heart Association, Council for High Blood Pressure Research
  • 2002, Hamilton Fellow, The Medical College of Georgia
  • 2000, The Caroline tum Suden/Frances A. Hellbrant Professional Opportunity Award; Searle Young Investigator Award at the 26th International Aldosterone Conference; Poster presentation Award for the University System of Georgia Research Symposium; International Society for Hypertension Young Investigator’s Award
  • 1999, Hall Fellowship; European Society for Hypertension Young Investigator’s Award
  • 1993, Chest, Heart and Stroke Vacation Scholarship
  • 1992, The Nuffield Foundation Undergraduate Bursary
  • 1991, Wellcome Trust Vacation Scholarship

Committees & Activities

Committees (Since 2007)

Michigan State University

  • 2007-present, Graduate Program Committee, Pharmacology and Toxicology; Program Director, 2009-present
  • 2010, Search Committee to identify an Assistant/Associate Professor, Pharmacology and Toxicology
  • 2010, Biomolecular Umbrella Program Working Group
  • 2011, MMD search Committee to identify a Hannah Chair and an Assistant Professor
  • 2011, Biomolecular Science Gateway Search Committee to identify a Director

National

  • 2006-2008, Ad hoc reviewer, Brain Injury and Neurovascular Pathologies Study Section, NIH; Permanent Member, 2008-present
  • 2009, American Diabetes Association Representative at the Annual Meeting of the Order of the Amaranth
  • 2009-present, Abstract Reviewer for The International Stroke Conference and The Council for High Blood Pressure Research
  • 2010, Ph.D. Thesis reader and Examiner, Department of Physiology, Medical College of Georgia
  • 2011, Co-Chair, AHA SURF Study Section
  • 2012-present, Member, APS Women in Physiology Committee

International

  • 2008, Ad hoc reviewer, Wellcome Trust, United Kingdom
  • 2009, Ph.D. Thesis Examiner, Monash University, Melbourne, Australia
  • 2011, Abstract Reviewer, 25th International Symposium on Cerebral Blood Flow Metabolism, and Function & 10th International Conference on Quantification of Brain Function with PET (BrainPET 11)

Editorial Duties

  • 2010-present, Editorial Board of Hypertension and the American Journal of Physiology-Heart and Circulatory Physiology
  • 2006-present, Editorial Board of Stroke
  • 2003-2006, Editorial Board of Endocrinology
  • Ad Hoc Reviewer for: American Journal of Hypertension, American Journal of Physiology (Endocrinology and Metabolism, Heart and Circulatory Physiology, and Regulatory, Integrative and Comparative Physiology), Brain Research, Circulation, Clinical Science, European Journal of Pharmacology, Hypertension, Journal of Hypertension, Journal of Neuroscience Methods, Molecular and Cellular Endocrinology, Neuropharmacology, Vascular Pharmacology

Publications

  • Mentoring 101: training for the future. Ayala-Lopez N, Matin N, Dorrance AM. Physiologist. 2013 Sep;56(5):153-4. No abstract available.PMID: 24175397[PubMed - indexed for MEDLINE]
  • Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor
    Pires, P. W., Jackson, W. F. & Dorrance, A. M. Jul 6 2015 In : American Journal of Physiology - Heart and Circulatory Physiology. 309, 1, p. H127-H136
  • Interfering with mineralocorticoid receptor activation: The past, present, and future
    Dorrance, A. M. 2014 In : F1000Prime Reports. 6, 61
  • Temporary mineralocorticoid receptor antagonism during the development of hypertension improves cerebral artery dilation
    McClain, J. L. & Dorrance, A. M. 2014 In : Experimental Biology and Medicine. 239, 5, p. 619-627 9 p.
  • Leukemia. 2013 Dec;27(12):2379-82. doi: 10.1038/leu.2013.147. Epub 2013 May 10. No abstract available. PMID: 23660685 [PubMed - in process]

Additional articles at PubMed